Cargando…

Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model

BACKGROUND: Nowadays MDMA (3,4-methylendioxymethamphetamine), known as ecstasy, is widely abused among the youth because of euphoria induction in acute exposure. However, abusers are predisposed to depression in chronic consumption of this illicit compound. Mirtazapine (MRZ), an antidepressant agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamshidfar, Sanaz, Ardakani, Yalda H., Lavasani, Hoda, Rouini, Mohammadreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490157/
https://www.ncbi.nlm.nih.gov/pubmed/28659160
http://dx.doi.org/10.1186/s40199-017-0183-z
_version_ 1783246929492180992
author Jamshidfar, Sanaz
Ardakani, Yalda H.
Lavasani, Hoda
Rouini, Mohammadreza
author_facet Jamshidfar, Sanaz
Ardakani, Yalda H.
Lavasani, Hoda
Rouini, Mohammadreza
author_sort Jamshidfar, Sanaz
collection PubMed
description BACKGROUND: Nowadays MDMA (3,4-methylendioxymethamphetamine), known as ecstasy, is widely abused among the youth because of euphoria induction in acute exposure. However, abusers are predisposed to depression in chronic consumption of this illicit compound. Mirtazapine (MRZ), an antidepressant agent, may be prescribed in MDMA-induced depression. MRZ is extensively metabolized in liver by CYP450 isoenzymes. 8-hydroxymirtazapine (8-OH) is mainly produced by CYP2D6. N-desmethylmirtazapine (NDES) is generated by CYP3A4. MDMA is also metabolized by the mentioned isoenzymes and demonstrates mechanism-based inhibition (MBI) in association with CYP2D6. Several studies revealed that MDMA showed inhibitory effects on CYP3A4. In the present study, our aim was to evaluate the impact of MDMA on the metabolism of MRZ in liver. Therefore, isolated perfused rat liver model was applied as our model of choice in this assessment. METHODS: The subjects of the study were categorized into two experimental groups. Rats in the control group received MRZ-containing Krebs-Henselit buffer (1 μg/ml). Rats in the treatment group received aqueous solution of 1 mg/ml MDMA (3 mg/kg) intraperitoneally 1 hour before receiving MRZ. Perfusate samples were analyzed by HPLC. RESULTS: Analyses of perfusate samples showed 80% increase in the parent drug concentrations and 50% decrease in the concentrations of both metabolites in our treatment group compared to the control group. In the treatment group compared to the control group, AUC((0–120)) of the parent drug demonstrated 50% increase and AUC((0–120)) of 8-OH and NDES showed 70% and 60% decrease, respectively. Observed decrease in metabolic ratios were 83% and 79% for 8-OH and NDES in treatment group compared to control group, respectively. Hepatic clearance (CL(h)) and intrinsic clearance (Cl(int)) showed 20% and 60% decrease in treatment group compared to control group. CONCLUSION: All findings prove the inhibitory effects of ecstasy on both CYP2D6 and CYP3A4 hepatic isoenzymes. In conclusion, this study is the first investigation of MRZ metabolism in presence of MDMA in isolated perfused rat liver model. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-5490157
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54901572017-06-30 Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model Jamshidfar, Sanaz Ardakani, Yalda H. Lavasani, Hoda Rouini, Mohammadreza Daru Short Communication BACKGROUND: Nowadays MDMA (3,4-methylendioxymethamphetamine), known as ecstasy, is widely abused among the youth because of euphoria induction in acute exposure. However, abusers are predisposed to depression in chronic consumption of this illicit compound. Mirtazapine (MRZ), an antidepressant agent, may be prescribed in MDMA-induced depression. MRZ is extensively metabolized in liver by CYP450 isoenzymes. 8-hydroxymirtazapine (8-OH) is mainly produced by CYP2D6. N-desmethylmirtazapine (NDES) is generated by CYP3A4. MDMA is also metabolized by the mentioned isoenzymes and demonstrates mechanism-based inhibition (MBI) in association with CYP2D6. Several studies revealed that MDMA showed inhibitory effects on CYP3A4. In the present study, our aim was to evaluate the impact of MDMA on the metabolism of MRZ in liver. Therefore, isolated perfused rat liver model was applied as our model of choice in this assessment. METHODS: The subjects of the study were categorized into two experimental groups. Rats in the control group received MRZ-containing Krebs-Henselit buffer (1 μg/ml). Rats in the treatment group received aqueous solution of 1 mg/ml MDMA (3 mg/kg) intraperitoneally 1 hour before receiving MRZ. Perfusate samples were analyzed by HPLC. RESULTS: Analyses of perfusate samples showed 80% increase in the parent drug concentrations and 50% decrease in the concentrations of both metabolites in our treatment group compared to the control group. In the treatment group compared to the control group, AUC((0–120)) of the parent drug demonstrated 50% increase and AUC((0–120)) of 8-OH and NDES showed 70% and 60% decrease, respectively. Observed decrease in metabolic ratios were 83% and 79% for 8-OH and NDES in treatment group compared to control group, respectively. Hepatic clearance (CL(h)) and intrinsic clearance (Cl(int)) showed 20% and 60% decrease in treatment group compared to control group. CONCLUSION: All findings prove the inhibitory effects of ecstasy on both CYP2D6 and CYP3A4 hepatic isoenzymes. In conclusion, this study is the first investigation of MRZ metabolism in presence of MDMA in isolated perfused rat liver model. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2017-06-28 /pmc/articles/PMC5490157/ /pubmed/28659160 http://dx.doi.org/10.1186/s40199-017-0183-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Communication
Jamshidfar, Sanaz
Ardakani, Yalda H.
Lavasani, Hoda
Rouini, Mohammadreza
Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model
title Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model
title_full Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model
title_fullStr Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model
title_full_unstemmed Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model
title_short Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model
title_sort inhibition of mirtazapine metabolism by ecstasy (mdma) in isolated perfused rat liver model
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490157/
https://www.ncbi.nlm.nih.gov/pubmed/28659160
http://dx.doi.org/10.1186/s40199-017-0183-z
work_keys_str_mv AT jamshidfarsanaz inhibitionofmirtazapinemetabolismbyecstasymdmainisolatedperfusedratlivermodel
AT ardakaniyaldah inhibitionofmirtazapinemetabolismbyecstasymdmainisolatedperfusedratlivermodel
AT lavasanihoda inhibitionofmirtazapinemetabolismbyecstasymdmainisolatedperfusedratlivermodel
AT rouinimohammadreza inhibitionofmirtazapinemetabolismbyecstasymdmainisolatedperfusedratlivermodel